What topics does this cannabis study cover?

This study covers research on: Endocannabinoid, THC, Neuroprotection.

Where was this research published?

Published in Nature reviews. Neuroscience on October 16, 2026.

Review links declining endocannabinoid activity to brain ageing; human…

Q: What did this Review find?

The review describes *endocannabinoid* signalling as declining during ageing after relatively high activity in early adulthood.

The endocannabinoid system and the ageing brain.

Nature reviews. Neuroscience • October 16, 2026 • Review • Highly Relevant

🤖

AI Summary

This review examines how the endocannabinoid system changes with age and may relate to brain ageing. It describes this lipid-signalling network as helping maintain balance in neurons, glial cells, metabolism and inflammation. Its activity follows a lifespan pattern, generally declining during ageing, while disruption of the system can impair processes associated with brain ageing, including neuroinflammation control, neurogenesis, synaptic plasticity and cognition.

The review also reports that low-dose THC can improve some ageing-related brain features in old animals. That animal evidence does not establish a benefit in people: the abstract says clinical evidence in older humans is limited and that cannabinoid-based approaches need further evaluation. This is an abstract-based summary of a review; it cannot establish treatment effectiveness or determine whether findings in animals apply to older humans.

💡 Key Findings

The review describes endocannabinoid signalling as declining during ageing after relatively high activity in early adulthood.

High

90%

Disrupting endocannabinoid system activity impairs several processes linked to brain ageing, including inflammatory control, neurogenesis, synaptic plasticity and cognitive performance.

High

90%

Low-dose THC can ameliorate several ageing-related brain phenotypes in old animals, according to the review; this does not establish benefit in humans.

High

85%

Clinical evidence in older humans remains limited, and the therapeutic potential of cannabinoid-based interventions requires further evaluation.

High

95%

📄 Original Abstract

Ageing is accompanied by a progressive decline in homeostatic resilience that increases vulnerability to chronic disease, disability and cognitive impairment. Although unhealthy brain ageing can often be prevented by managing the underlying risk factors, the molecular, cellular and physiological mechanisms that connect risk factors to late-life brain dysfunction remain incompletely understood. This review examines the role of the endocannabinoid system in brain ageing. The endocannabinoid system is a short-range lipid signalling network that helps to maintain neuronal, glial, metabolic and inflammatory homeostasis. Endocannabinoid signalling follows a dynamic lifespan trajectory, with relatively high activity during early adulthood and functional decline during ageing. Genetic or pharmacological disruption of endocannabinoid system activity impairs several processes linked to hallmarks of brain ageing, including neuroinflammatory control, adult neurogenesis, synaptic plasticity, cognitive performance, metabolic regulation and epigenetic stability. Conversely, low-dose Δ9-tetrahydrocannabinol (THC) treatment can ameliorate several ageing-related brain phenotypes in old animals. However, clinical evidence in older humans remains limited, and the therapeutic potential of cannabinoid-based interventions requires further evaluation.